Abstract
ACTH-independent macronodular adrenal hyperplasia (AIMAH) is a very rare cause of endogenous Cushing’s syndrome (CS). In this review, the clinical characteristics, the pathophysiology, and the management of AIMAH are described. AIMAH typically presents with overt CS, but subclinical oversecretion of cortisol has been increasingly described. The diagnosis is suspected by adrenal nodular enlargement on conventional imaging following the demonstration of ACTH-independent hypercortisolism. Final diagnosis is established by histological examination of the adrenal tissue. Bilateral adrenalectomy is the treatment of choice but unilateral adrenalectomy has been proposed in selected cases. In patients with subclinical CS, the decision to treat should be individualized. The pathophysiology of this condition has begun to be elucidated in recent years. Diverse aberrant membrane-bound receptors expressed in a non-mutated form in the adrenal gland have been found to be implicated in the regulation of steroidogenesis in AIMAH. When systematically screened, most patients with AIMAH and CS or subclinical CS exhibit an in vivo aberrant cortisol response to one or various ligands suggesting the presence of aberrant adrenal receptors. A protocol designed to screen patients for the presence of these aberrant receptors should be undertaken in all patients with AIMAH. The identification of these receptors provides the potential for novel pharmacological therapies by suppressing the endogenous ligands or blocking the receptor with specific antagonists.
References
1.
Nieman LK: Cushing’s syndrome; in De Groot LJ, Jameson JLe, Burger HG, et al (eds): Endocrinology, ed 4. Philadelphia, Saunders, 2000, pp 1691–1720.
2.
Lieberman SA, Eccleshall TR, Feldman D: ACTH-independent massive bilateral adrenal disease (AIMBAD): A subtype of Cushing’s syndrome with major diagnostic and therapeutic implications. Eur J Endocrinol 1994;131:67–73.
3.
Stratakis CA, Kirschner LS: Clinical and genetic analysis of primary bilateral adrenal diseases (micro- and macronodular disease) leading to Cushing syndrome. Horm Metab Res 1998;30:456–463.
4.
Swain JM, Grant CS, Schlinkert RT, Thompson GB, van Heerden JA, Lloyd RV, Young WF: Corticotropin-independent macronodular adrenal hyperplasia: A clinicopathologic correlation. Arch Surg 1998;133:541–545.
5.
Kirschner MA, Powell RD Jr, Lipsett MB: Cushing’s syndrome: Nodular cortical hyperplasia of adrenal glands with clinical and pathological features suggesting adrenocortical tumor. J Clin Endocrinol Metab 1964;24:947– 955.
6.
Kirk JM, Brain CE, Carson DJ, Hyde JC, Grant DB: Cushing’s syndrome caused by nodular adrenal hyperplasia in children with McCune-Albright syndrome. J Pediatr 1999;134:789–792.
7.
Malchoff CD, MacGillivray D, Malchoff DM: Adrenocorticotropic hormone-independent adrenal hyperplasia. Endocrinologist 1996;6:79–85.
8.
Zeiger MA, Nieman LK, Cutler GB, Chrousos GP, Doppman JL, Travis WD, Norton JA: Primary bilateral adrenocortical causes of Cushing’s syndrome. Surgery 1991;110:1106–1115.
9.
Aiba M, Hirayama A, Iri H, Ito Y, Fujimoto Y, Mabuchi G, Murai M, Tazaki H, Maruyama H, Saruta T: Adrenocorticotropic hormone-independent bilateral adrenocortical macronodular hyperplasia as a distinct subtype of Cushing’s syndrome. Enzyme histochemical and ultrastructural study of four cases with a review of the literature. Am J Clin Pathol 1991;96:334–340.
10.
Lacroix A, N’Diaye N, Tremblay J, Hamet P: Ectopic and abnormal hormone receptors in adrenal Cushing’s syndrome. Endocr Rev 2001;22:75–110.
11.
Minami S, Sugihara H, Sato J, Tatsukuchi A, Sugisaki Y, Sasano H, Wakabayashi I: ACTH independent Cushing’s syndrome occurring in siblings. Clin Endocrinol (Oxf) 1996;44:483–488.
12.
Nies C, Bartsch DK, Ehlenz K, Wild A, Langer P, Fleischhacker S, Rothmund M: Familial ACTH-independent Cushing’s syndrome with bilateral macronodular adrenal hyperplasia clinically affecting only female family members. Exp Clin Endocrinol Diabetes 2002;110:277–283.
13.
Findlay JC, Sheeler LR, Engeland WC, Aron DC: Familial adrenocorticotropin-independent Cushing’s syndrome with bilateral macronodular adrenal hyperplasia. J Clin Endocrinol Metab 1993;76:189–191.
14.
Imohl M, Koditz R, Stachon A, Muller KM, Nicolas V, Pfeilschifter J, Krieg M: Catecholamine-dependent hereditary Cushing’s syndrome – Follow-up after unilateral adrenalectomy (in German). Med Klin (Munich) 2002;97:747–753.
15.
Lee S, Jun S, Hong SW, Kim DJ, Rhee Y, Lim SK: Familial adrenocorticotropin-independent macronodular adrenal hyperplasia: Ectopic expression of vasopressin V1b, V2 receptors in the adrenal gland (abstract). 86th Meeting of the Endocrine Society, New Orleans, 2004, p 566.
16.
Bourdeau I, D’Amour P, Hamet P, Boutin JM, Lacroix A: Aberrant membrane hormone receptors in incidentally discovered bilateral macronodular adrenal hyperplasia with subclinical Cushing’s syndrome. J Clin Endocrinol Metab 2001;86:5534–5540.
17.
Ohashi A, Yamada Y, Sakaguchi K, Inoue T, Kubo M, Fushimi H: A natural history of adrenocorticotropin-independent bilateral adrenal macronodular hyperplasia (AIMAH) from preclinical to clinically overt Cushing’s syndrome. Endocr J 2001;48:677–683.
18.
Yamada Y, Sakaguchi K, Inoue T, Kubo M, Fushimi H, Sekii K, Itatani H, Tsujimura T, Kameyama M: Preclinical Cushing’s syndrome due to adrenocorticotropin-independent bilateral adrenocortical macronodular hyperplasia with concurrent excess of gluco- and mineralocorticoids. Intern Med 1997;36:628–632.
19.
Hayashi Y, Takeda Y, Kaneko K, Koyama H, Aiba M, Ikeda U, Shimada K: A case of Cushing’s syndrome due to ACTH-independent bilateral macronodular hyperplasia associated with excessive secretion of mineralocorticoids. Endocr J 1998;45:485–491.
20.
Yared Z, Antonini S, Lacroix A: Macronodular adrenal hyperplasia with long-term primary hyperaldosteronism and recent cyclical Cushing’s syndrome with aberrant response of cortisol to serotonin agonist 5-HT4 R (abstract). 85th Meeting of the Endocrine Society, Philadelphia, 2003, p 445.
21.
Malchoff CD, Rosa J, DeBold CR, Kozol RA, Ramsby GR, Page DL, Malchoff DM, Orth DN: Adrenocorticotropin-independent bilateral macronodular adrenal hyperplasia: An unusual cause of Cushing’s syndrome. J Clin Endocrinol Metab 1989;68:855–860.
22.
Goodarzi MO, Dawson DW, Li X, Lei Z, Shintaku P, Rao CV, Van Herle AJ: Virilization in bilateral macronodular adrenal hyperplasia controlled by luteinizing hormone. J Clin Endocrinol Metab 2003;88:73–77.
23.
Doppman JL, Nieman LK, Travis WD, Miller DL, Cutler GB Jr, Chrousos GP, Norton JA: CT and MR imaging of massive macronodular adrenocortical disease: A rare cause of autonomous primary adrenal hypercortisolism. J Comput Assist Tomogr 1991;15:773–779.
24.
Rockall AG, Babar SA, Sohaib SA, Isidori AM, Diaz-Cano S, Monson JP, Grossman AB, Reznek RH: CT and MR imaging of the adrenal glands in ACTH-independent Cushing syndrome. Radiographics 2004;24:435–452.
25.
N’Diaye N, Hamet P, Tremblay J, Boutin JM, Gaboury L, Lacroix A: Asynchronous development of bilateral nodular adrenal hyperplasia in gastric inhibitory polypeptide-dependent Cushing’s syndrome. J Clin Endocrinol Metab 1999;84:2616–2622.
26.
Doppman JL, Chrousos GP, Papanicolaou DA, Stratakis CA, Alexander HR, Nieman LK: Adrenocorticotropin-independent macronodular adrenal hyperplasia: An uncommon cause of primary adrenal hypercortisolism. Radiology 2000;216:797–802.
27.
Smals AG, Pieters GF, van Haelst UJ, Kloppenborg PW: Macronodular adrenocortical hyperplasia in long-standing Cushing’s disease. J Clin Endocrinol Metab 1984;58:25–31.
28.
Sasano H, Suzuki T, Nagura H: ACTH-independent macronodular adrenocortical hyperplasia: Immunohistochemical and in situ hybridization studies of steroidogenic enzymes. Mod Pathol 1994;7:215–219.
29.
Aiba M, Kawakami M, Ito Y, Fujimoto Y, Suda T, Demura H: Bilateral adrenocortical adenomas causing Cushing’s syndrome. Report of two cases with enzyme histochemical and ultrastructural studies and a review of the literature. Arch Pathol Lab Med 1992;116:146–150.
30.
Cugini P, Battisti P, Di Palma L, Sepe M, Kawasaki T, Uezono K, Sasaki H: ‘GIANT’ macronodular adrenal hyperplasia causing Cushing’s syndrome: Case report and review of the literature on a clinical distinction of adrenocortical nodular pathology associated with hypercortisolism. Endocrinol Jpn 1989;36:101–116.
31.
Koizumi S, Beniko M, Ikota A, Mizumoto H, Matsuya K, Matsuda A, Sakuma S, Mashio Y, Kunita H, Okamoto K: Adrenocorticotropic hormone-independent bilateral adrenocortical macronodular hyperplasia: A case report and immunohistochemical studies. Endocr J 1994;41:429–435.
32.
Wada N, Kubo M, Kijima H, Ishizuka T, Saeki T, Koike T, Sasano H: Adrenocorticotropin-independent bilateral macronodular adrenocortical hyperplasia: Immunohistochemical studies of steroidogenic enzymes and post-operative course in two men. Eur J Endocrinol 1996;134:583–587.
33.
Morioka M, Ohashi Y, Watanabe H, Komatsu F, Jin TX, Suyama B, Tanaka H: ACTH-independent macronodular adrenocortical hyperplasia (AIMAH): Report of two cases and the analysis of steroidogenic activity in adrenal nodules. Endocr J 1997;44:65–72.
34.
Sasano H: Localization of steroidogenic enzymes in adrenal cortex and its disorders. Endocr J 1994;41:471–482.
35.
Bourdeau I, Antonini S, Lacroix A, Kirschner LS, Lorang D, Libutti SK, Stratakis CA: Gene array analysis of macronodular adrenal hyperplasia confirms clinical heterogeneity and identifies several genes as molecular mediators. Oncogene 2004;26:1575–1585.
36.
Bourdeau I, D’Amour P, Hamet P, Boutin J-M, Lacroix A: Aberrant membrane hormone receptors in incidentally discovered bilateral macronodular adrenal hyperplasia with subclinical Cushing’s syndrome. J Clin Endocrinol Metab 2001;86:5534–5540.
37.
Doppman JL, Miller DL, Dwyer AJ, Loughlin T, Nieman L, Cutler GB, Chrousos GP, Oldfield E, Loriaux DL: Macronodular adrenal hyperplasia in Cushing disease. Radiology 1988;166:347–352.
38.
Hermus AR, Pieters GF, Smals AG, Pesman GJ, Lamberts SW, Benraad TJ, van Haelst UJ, Kloppenborg PW: Transition from pituitary-dependent to adrenal-dependent Cushing’s syndrome. N Engl J Med 1988;318:966–970.
39.
Sturrock ND, Morgan L, Jeffcoate WJ: Autonomous nodular hyperplasia of the adrenal cortex: Tertiary hypercortisolism? Clin Endocrinol (Oxf) 1995;43:753–758.
40.
Hocher B, Bahr V, Dorfmuller S, Oelkers W: Hypercortisolism with non-pigmented micronodular adrenal hyperplasia: Transition from pituitary-dependent to adrenal-dependent Cushing’s syndrome. Acta Endocrinol (Copenh) 1993;128:120–125.
41.
Choi Y, Werk EE, Jr., Sholiton LJ: Cushing’s syndrome with dual pituitary-adrenal control. Arch Intern Med 1970;125:1045–1049.
42.
Aron DC, Findling JW, Fitzgerald PA, Brooks RM, Fisher FE, Forsham PH, Tyrrell JB: Pituitary ACTH dependency of nodular adrenal hyperplasia in Cushing’s syndrome. Report of two cases and review of the literature. Am J Med 1981;71:302–306.
43.
Cheitlin RA, Westphal M, Cabrera CM, Fujii DK, Snyder J, Fitzgerald PA: Cushing’s syndrome due to bilateral adrenal macronodular hyperplasia with undetectable ACTH: Cell culture of adenoma cells on extracellular matrix. Horm Res 1988;29:162–167.
44.
Light K, Jenkins PJ, Weber A, Perrett C, Grossman A, Pistorello M, Asa SL, Clayton RN, Clark AJ: Are activating mutations of the adrenocorticotropin receptor involved in adrenal cortical neoplasia? Life Sci 1995;56:1523–1527.
45.
Latronico AC, Reincke M, Mendonca BB, Arai K, Mora P, Allolio B, Wajchenberg BL, Chrousos GP, Tsigos C: No evidence for oncogenic mutations in the adrenocorticotropin receptor gene in human adrenocortical neoplasms. J Clin Endocrinol Metab 1995;80:875–877.
46.
Fragoso MC, Domenice S, Latronico AC, Martin RM, Pereira MA, Zerbini MC, Lucon AM, Mendonca BB: Cushing’s syndrome secondary to adrenocorticotropin-independent macronodular adrenocortical hyperplasia due to activating mutations of GNAS1 gene. J Clin Endocrinol Metab 2003;88:2147–2151.
47.
Swords FM, Baig A, Malchoff DM, Malchoff CD, Thorner MO, King PJ, Hunyady L, Clark AJ: Impaired desensitization of a mutant adrenocorticotropin receptor associated with apparent constitutive activity. Mol Endocrinol 2002;16:2746–2753.
48.
Swords FM, Noon LA, King PJ, Clark AJ: Constitutive activation of the human ACTH receptor resulting from a synergistic interaction between two naturally occurring missence mutations in the MC2R gene. Mol Cell Endocrinol 2004;213:149–154.
49.
Aarskog D, Tveteraas E: McCune-Albright’s syndrome following adrenalectomy for Cushing’s syndrome in infancy. J Pediatr 1968;73:89–96.
50.
Benjamin DR, McRoberts JW: Polyostotic fibrous dysplasia associated with Cushing syndrome. Arch Pathol 1973;96:175–178.
51.
Mauras N, Blizzard RM: The McCune-Albright syndrome. Acta Endocrinol Suppl (Copenh) 1986;279:207–217.
52.
Shenker A, Laue L, Kosugi S, Merendino JJJ, Minegishi T, Cutler GBJ: A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty. Nature 1993;365:652–654.
53.
MacMahon HE: Albright’s syndrome – Thirty years later. (Polyostotic fibrous dysplasia). Pathol Annu 1971;6:81–146.
54.
Danon M, Robboy SJ, Kim S, Scully R, Crawford JD: Cushing syndrome, sexual precocity, and polyostotic fibrous dysplasia (Albright syndrome) in infancy. J Pediatr 1975;87:917–921.
55.
Bourdeau I, Lacroix A: G-protein mutations (Gsα and G12α) are infrequent in the adrenal tissues with Cushing’s syndrome secondary to ACTH-independent bilateral macronodular adrenal hyperplasia (abstract). 84th Meeting of the Endocrine Society, 2002, p 244.
56.
Skogseid B, Larsson C, Lindgren PG, Kvanta E, Rastad J, Theodorsson Wide L, Wilander E, Oberg K: Clinical and genetic features of adrenocortical lesions in multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 1992;75:76–81.
57.
Yamakita N, Murai T, Ito Y, Miura K, Ikeda T, Miyamoto K, Onami S, Yoshida T: Adrenocorticotropin-independent macronodular adrenocortical hyperplasia associated with multiple colon adenomas/carcinomas which showed a point mutation in the APC gene. Intern Med 1997;36:536–542.
58.
Marchesa P, Fazio VW, Church JM, McGannon E: Adrenal masses in patients with familial adenomatous polyposis. Dis Colon Rectum 1997;40:1023–1028.
59.
Schorr I, Ney RL: Abnormal hormone responses of an adrenocortical cancer adenyl cyclase. J Clin Invest 1971;50:1295–1300.
60.
Hamet P, Larochelle P, Franks DJ, Cartier P, Bolte E: Cushing syndrome with food-dependent periodic hormonogenesis. Clin Invest Med 1987;10:530–533.
61.
Lacroix A, Bolte E, Tremblay J, Dupre J, Poitras P, Fournier H, Garon J, Garrel D, Bayard F, Taillefer R, Flanagan RJ, Hamet P: Gastric inhibitory polypeptide-dependent cortisol hypersecretion – A new cause of Cushing’s syndrome. N Engl J Med 1992;327:974–980.
62.
Reznik Y, Allali-Zerah V, Chayvialle JA, Leroyer R, Leymarie P, Travert G, Lebrethon MC, Budi I, Balliere AM, Mahoudeau J: Food-dependent Cushing’s syndrome mediated by aberrant adrenal sensitivity to gastric inhibitory polypeptide. N Engl J Med 1992;327:981–986.
63.
Lebrethon MC, Avallet O, Reznik Y, Archambeaud F, Combes J, Usdin TB, Narboni G, Mahoudeau J, Saez JM: Food-dependent Cushing’s syndrome: Characterization and functional role of gastric inhibitory polypeptide receptor in the adrenals of three patients. J Clin Endocrinol Metab 1998;83:4514–4519.
64.
Pralong FP, Gomez F, Guillou L, Mosimann F, Franscella S, Gaillard RC: Food-dependent Cushing’s syndrome: Possible involvement of leptin in cortisol hypersecretion. J Clin Endocrinol Metab 1999;84:3817–3822.
65.
Gerl H, Rohde W, Biering H, Schulz N, Lochs H: Food-dependent Cushing syndrome of long standing with mild clinical features (in German). Dtsch Med Wochenschr 2000;125:1565–1568.
66.
Groussin L, Perlemoine K, Contesse V, Lefebvre H, Tabarin A, Thieblot P, Schlienger JL, Luton JP, Bertagna X, Bertherat J: The ectopic expression of the gastric inhibitory polypeptide receptor is frequent in adrenocorticotropin-independent bilateral macronodular adrenal hyperplasia, but rare in unilateral tumors. J Clin Endocrinol Metab 2002;87:1980–1985.
67.
Croughs RJ, Zelissen PM, Van Vroonhoven ThJ, Hofland LJ, N’Diaye N, Lacroix A, de Herder WW: GIP-dependent adrenal Cushing’s syndrome with incomplete suppression of ACTH. Clin Endocrinol (Oxf) 2000;52:235–240.
68.
Chabre O, Liakos P, Vivier J, Chaffanjon P, Labat-Moleur F, Martinie M, Bottari SP, Bachelot I, Chambaz EM, Defaye G, Feige JJ: Cushing’s syndrome due to a gastric inhibitory polypeptide-dependent adrenal adenoma: Insights into hormonal control of adrenocortical tumorigenesis. J Clin Endocrinol Metab 1998;83:3134–3143.
69.
de Herder WW, Hofland LJ, Usdin TB, de Jong FH, Uitterlinden P, van Koetsveld P, Mezey E, Bonner TI, Bonjer HJ, Lamberts SW: Food-dependent Cushing’s syndrome resulting from abundant expression of gastric inhibitory polypeptide receptors in adrenal adenoma cells. J Clin Endocrinol Metab 1996;81:3168–3172.
70.
Luton JP, Bertagna X: Membrane receptors and endocrine tumors: Expression of vasopressin receptor V1 modulates the pharmacologic phenotype of adrenocortical tumors (in French). Bull Acad Natl Med 1998;182:299–309.
71.
Tsagarakis S, Tsigos C, Vassiliou V, Tsiotra P, Pratsinis H, Kletsas D, Trivizas P, Nikou A, Mavromatis T, Sotsiou F, Raptis S, Thalassinos N: Food-dependent androgen and cortisol secretion by a gastric inhibitory polypeptide-receptor expressive adrenocortical adenoma leading to hirsutism and subclinical Cushing’s syndrome: In vivo and in vitro studies. J Clin Endocrinol Metab 2001;86:583–589.
72.
N’Diaye N, Tremblay J, Hamet P, de Herder WW, Lacroix A: Adrenocortical overexpression of gastric inhibitory polypeptide receptor underlies food-dependent Cushing’s syndrome. J Clin Endocrinol Metab 1998;83:2781–2785.
73.
Longo-Mazzuco T, Chabre O, Feige JJ, Thomas M: Démonstration du potentiel transformant du gène du récepteur du GIP dans les cellules du cortex surrénalien: un pas vers l’étiologie du syndrome de Cushing lié à l’alimentation. Ann Endocrinol (Paris) 2004;65:267.
74.
Arnaldi G, Gasc JM, de Keyzer Y, Raffin-Sanson ML, Perraudin V, Kuhn JM, Raux-Demay MC, Luton JP, Clauser E, Bertagna X: Variable expression of the V1 vasopressin receptor modulates the phenotypic response of steroid-secreting adrenocortical tumors. J Clin Endocrinol Metab 1998;83:2029–2035.
75.
Campbell KK, Baysdorfer C, Antonini S, Lacroix A: V1 vasopressin receptor sequence and expression in adrenal Cushing’s syndrome with aberrant response to vasopressin (abstract). 86th Meeting of the Endocrine Society, New Orleans, 2004, p 566.
76.
Louiset E, Contesse V, Cartier D, Bertherat J, Duparc C, Barrande G, Groussin L, Vaudry H, Lefebvre H: Pharmacological profile and coupling mechanisms of illegitimate receptors in ACTH-independent macronodular bilateral adrenal hyperplasia causing Cushing’s syndrome (abstract). 86th Meeting of the Endocrine Society, New Orleans, 2004, p 564.
77.
Mune T, Murase H, Yamakita N, Fukuda T, Murayama M, Miura A, Suwa T, Hanafusa J, Daido H, Morita H, Yasuda K: Eutopic overexpression of vasopressin V1a receptor in adrenocorticotropin-independent macronodular adrenal hyperplasia. J Clin Endocrinol Metab 2002;87:5706–5713.
78.
Beuschlein F, Reincke M, Karl M, Travis WD, Jaursch-Hancke C, Abdelhamid S, Chrousos GP, Allolio B: Clonal composition of human adrenocortical neoplasms. Cancer Res 1994;54:4927–4932.
79.
Daidoh H, Morita H, Hanafusa J, Mune T, Murase H, Sato M, Shibata T, Suwa T, Ishizuka T, Yasuda K: In vivo and in vitro effects of AVP and V1a receptor antagonist on Cushing’s syndrome due to ACTH-independent bilateral macronodular adrenocortical hyperplasia. Clin Endocrinol (Oxf) 1998;49:403–409.
80.
Horiba N, Suda T, Aiba M, Naruse M, Nomura K, Imamura M, Demura H: Lysine vasopressin stimulation of cortisol secretion in patients with adrenocorticotropin-independent macronodular adrenal hyperplasia. J Clin Endocrinol Metab 1995;80:2336–2341.
81.
Iida K, Kaji H, Matsumoto H, Okimura Y, Abe H, Fujisawa M, Kamidono S, Chihara K: Adrenocorticotrophin-independent macronodular adrenal hyperplasia in a patient with lysine vasopressin responsiveness but insensitivity to gastric inhibitory polypeptide. Clin Endocrinol (Oxf) 1997;47:739–745.
82.
Lacroix A, Tremblay J, Touyz RM, Deng LY, Lariviere R, Cusson JR, Schiffrin EL, Hamet P: Abnormal adrenal and vascular responses to vasopressin mediated by a V1-vasopressin receptor in a patient with adrenocorticotropin-independent macronodular adrenal hyperplasia, Cushing’s syndrome, and orthostatic hypotension. J Clin Endocrinol Metab 1997;82:2414–2422.
83.
Mircescu H, Jilwan J, N’Diaye N, Bourdeau I, Tremblay J, Hamet P, Lacroix A: Are ectopic or abnormal membrane hormone receptors frequently present in adrenal Cushing’s syndrome? J Clin Endocrinol Metab 2000;85:3531–3536.
84.
Perraudin V, Delarue C, de Keyzer Y, Bertagna X, Kuhn JM, Contesse V, Clauser E, Vaudry H: Vasopressin-responsive adrenocortical tumor in a mild Cushing’s syndrome: In vivo and in vitro studies. J Clin Endocrinol Metab 1995;80:2661–2667.
85.
Pignatelli D, Rodrigues E, Barbosa AM, Medina JL: Cushing syndrome due to the ectopic expression of adrenergic receptors in the adrenal cortex. A case of ACTH independent macronodular adrenal hyperplasia (AIMAH) (abstract). 86th Meeting of the Endocrine Society, New Orleans, 2004, p 611.
86.
Lacroix A, Tremblay J, Rousseau G, Bouvier M, Hamet P: Propranolol therapy for ectopic beta-adrenergic receptors in adrenal Cushing’s syndrome. N Engl J Med 1997;337:1429–1434.
87.
Miyamura N, Tsutsumi A, Senokuchi H, Nakamaru K, Kawashima J, Sakai K, Taguchi T, Tokunaga H, Nishida K, Uehara M, Sakakida M, Araki E: A case of ACTH-independent macronodular adrenal hyperplasia: Simultaneous expression of several aberrant hormone receptors in the adrenal gland. Endocr J 2003;50:333–340.
88.
Segaloff DL, Ascoli M: The lutropin/choriogonadotropin receptor. 4 years later. Endocr Rev 1993;14:324–347.
89.
Pabon JE, Li X, Lei ZM, Sanfilippo JS, Yussman MA, Rao CV: Novel presence of luteinizing hormone/chorionic gonadotropin receptors in human adrenal glands. J Clin Endocrinol Metab 1996;81:2397–2400.
90.
Seron-Ferre M, Lawrence CC, Jaffe RB: Role of hCG in regulation of the fetal zone of the human fetal adrenal gland. J Clin Endocrinol Metab 1978;46:834–837.
91.
Lacroix A, Hamet P, Boutin JM: Leuprolide acetate therapy in luteinizing hormone-dependent Cushing’s syndrome. N Engl J Med 1999;341:1577–1581.
92.
N’Diaye N, Cartier D, Bourdeau I, Tremblay J, Hamet P, Lefebvre H, Lacroix A: Characterization of aberrant LH/hCG and serotonin 5-HT4 receptors in adrenal Cushing’s syndrome (abstract). 83rd Annual Meeting of the Endocrine Society, Denver, 2001, p 235.
93.
Feelders RA, Lamberts SW, Hofland LJ, van Koetsveld PM, Verhoef-Post M, Themmen AP, de Jong FH, Bonjer HJ, Clark AJ, van der Lely AJ, de Herder WW: Luteinizing hormone (LH)-responsive Cushing’s syndrome: The demonstration of LH receptor messenger ribonucleic acid in hyperplastic adrenal cells, which respond to chorionic gonadotropin and serotonin agonists in vitro. J Clin Endocrinol Metab 2003;88:230–237.
94.
Bertherat J, Barrande G, Lefebvre H, Raffin-Sanson ML, Bertagna X: Systematic screening confirms that illicit membrane receptors are frequent and often multiple in bilateral ACTH-independent macronodular adrenal hyperplasia (AIMAH) (abstract). 83rd Annual Meeting of the Endocrine Society, Denver, 2001, p 233.
95.
Lefebvre H, Contesse V, Delarue C, Vaudry H, Kuhn JM: Serotonergic regulation of adrenocortical function. Horm Metab Res 1998;30:398–403.
96.
Cartier D, Lihrmann I, Parmentier F, Bastard C, Bertherat J, Caron P, Kuhn JM, Lacroix A, Tabarin A, Young J, Vaudry H, Lefebvre H: Overexpression of serotonin4 receptors in cisapride-responsive adrenocorticotropin-independent bilateral macronodular adrenal hyperplasia causing Cushing’s syndrome. J Clin Endocrinol Metab 2003;88:248–254.
97.
Mannelli M, Ferruzzi P, Luciani P, Crescioli C, Buci L, Corona G, Serio M, Peri A: Cushing’s syndrome in a patient with bilateral macronodular adrenal hyperplasia responding to cisapride: An in vivo and in vitro study. J Clin Endocrinol Metab 2003;88:4616–4622.
98.
Nakamura Y, Son Y, Kohno Y, Shimono D, Kuwamura N, Koshiyama H, Sasano H, Matsuda T: Case of adrenocorticotropic hormone-independent macronodular adrenal hyperplasia with possible adrenal hypersensitivity to angiotensin II. Endocrine 2001;15:57–61.
99.
Bertherat J, Contesse V, Louiset E, Barrande G, Duparc C, Groussin L, Emy P, Bertagna X, Kuhn JM, Vaudry H, Lefebvre H: Abnormal sensitivity of the adrenocortical tissue to multiple stimuli in ACTH-independent macronodular adrenal hyperplasia (AIMAH) causing Cushing’s syndrome: In vivo and in vitro studies (abstract). 86th Meeting of the Endocrine Society, New Orleans, 2004, p 562.
100.
Slieker LJ, Sloop KW, Surface PL, Kriauciunas A, LaQuier F, Manetta J, Bue-Valleskey J, Stephens TW: Regulation of expression of ob mRNA and protein by glucocorticoids and cAMP. J Biol Chem 1996;271:5301–5304.
101.
Glasow A, Bornstein SR, Chrousos GP, Brown JW, Scherbaum WA: Detection of Ob-receptor in human adrenal neoplasms and effect of leptin on adrenal cell proliferation. Horm Metab Res 1999;31:247–251.
102.
Pralong FP, Roduit R, Waeber G, Castillo E, Mosimann F, Thorens B, Gaillard RC: Leptin inhibits directly glucocorticoid secretion by normal human and rat adrenal gland. Endocrinology 1998;139:4264–4268.
103.
Makino S, Hashimoto K, Sugiyama M, Hirasawa R, Takao T, Ota Z, Saegusa M, Ohashi T, Omori H: Cushing’s syndrome due to huge nodular adrenocortical hyperplasia with fluctuation of urinary 17-OHCS excretion. Endocrinol Jpn 1989;36:655–663.
104.
Hashimoto K, Kawada Y, Murakami K, Hattori T, Suemaru S, Kageyama J, Ota Z, Hayata S, Ohashi T, Omori H: Cortisol responsiveness to insulin-induced hypoglycemia in Cushing’s syndrome with huge nodular adrenocortical hyperplasia. Endocrinol Jpn 1986;33:479–487.
105.
Lacroix A, Baldacchino V, Bourdeau I, Hamet P, Tremblay J: Cushing’s syndrome variants secondary to aberrant hormone receptors. Trends Endocrinol Metab 2004;15:375–382.
106.
Willenberg HS, Stratakis CA, Marx C, Ehrhart-Bornstein M, Chrousos GP, Bornstein SR: Aberrant interleukin-1 receptors in a cortisol-secreting adrenal adenoma causing Cushing’s syndrome. N Engl J Med 1998;339:27–31.
107.
Lefebvre H, Duparc C, Chartrel N, Jegou S, Pellerin A, Laquerriere A, Ivell R, Vaudry H, Kuhn JM: Intraadrenal adrenocorticotropin production in a case of bilateral macronodular adrenal hyperplasia causing Cushing’s syndrome. J Clin Endocrinol Metab 2003;88:3035–3042.
108.
Lacroix A, Mircescu H, Hamet P: Clinical evaluation of the presence of abnormal hormone receptors in adrenal Cushing’s syndrome. Endocrinologist 1999;9:9–15.
109.
Bertherat J, Barrande G, Lefebvre H, et al: Illegitimate membrane receptors are frequent and often multiple in bilateral ACTH-independent macronodular adrenal hyperplasia (abstract). 85th Meeting of the Endocrine Society, Philadelphia, 2003, p 570.
110.
Tatsuno I, Uchida D, Tanaka T, Koide H, Shigeta A, Ichikawa T, Sasano H, Saito Y: Vasopressin responsiveness of subclinical Cushing’s syndrome due to ACTH-independent macronodular adrenocortical hyperplasia. Clin Endocrinol (Oxf) 2004;60:192–200.
111.
Gicquel C, Leblond-Francillard M, Bertagna X, Louvel A, Chapuis Y, Luton JP, Girard F, Le Bouc Y: Clonal analysis of human adrenocortical carcinomas and secreting adenomas. Clin Endocrinol (Oxf) 1994;40:465–477.
112.
Gicquel C, Bertagna X, Le Bouc Y: Recent advances in the pathogenesis of adrenocortical tumours. Eur J Endocrinol 1995;133:133–144.
113.
Diaz-Cano SJ, de Miguel M, Blanes A, Tashjian R, Galera H, Wolfe HJ: Clonality as expression of distinctive cell kinetics patterns in nodular hyperplasias and adenomas of the adrenal cortex. Am J Pathol 2000;156:311–319.
114.
Antonini SR, N’Diaye N, Baldacchino V, Hamet P, Tremblay J, Lacroix A: Analysis of the putative regulatory region of the gastric inhibitory polypeptide receptor gene in food-dependent Cushing’s syndrome. J Steroid Biochem Mol Biol 2004;91:171–177.
115.
Baldacchino V, Oble S, Hamet P, Tremblay J, Lacroix A: Partial characterisation of the 5′ flanking region of the human GIP receptor (GIPR) gene. Endocr Res 2002;28:577.
116.
Kero J, Poutanen M, Zhang FP, Rahman N, McNicol AM, Nilson JH, Keri RA, Huhtaniemi IT: Elevated luteinizing hormone induces expression of its receptor and promotes steroidogenesis in the adrenal cortex. J Clin Invest 2000;105:633–641.
117.
Ogura M, Kusaka I, Nagasaka S, Yatagai T, Shinozaki S, Itabashi N, Nakamura T, Yokoyama M, Ishikawa SE, Ishibashi S: Unilateral adrenalectomy improves insulin resistance and diabetes mellitus in a patient with ACTH-independent macronodular adrenal hyperplasia. Endocr J 2003;50:715–721.
118.
Lamas C, Alfaro JJ, Lucas T, Lecumberri B, Barcelo B, Estrada J: Is unilateral adrenalectomy an alternative treatment for ACTH- independent macronodular adrenal hyperplasia? Long-term follow-up of four cases. Eur J Endocrinol 2002;146:237–240.
119.
Reincke M: Subclinical Cushing’s syndrome. Endocrinol Metab Clin North Am 2000;29:43–56.
120.
Yared Z, Bourdeau I, Lacroix A: Failure to control Cushing’s syndrome with leuprolide acetate in a case of ACTH-independent bilateral macronodular adrenal hyperplasia with partial regulation of cortisol secretion by LH and hCG (abstract). 84th Meeting of the Endocrine Society, San Francisco, 2002, p 649.
121.
Arteaga E, Mahana D, Gonzalez R, Martinez P: Cushing syndrome caused by macronodular adrenal hyperplasia, independent of ACTH: Report of a case (in Spanish). Rev Med Chil 1989;117:1398–1402.
122.
Lopez JM, Sapunar J, Donoso J, Martinez P: Cushing’s syndrome due to bilateral adrenal macronodular hyperplasia. From ACTH-dependent hypercortisolism to ACTH-independent hypercortisolism (in Spanish). Rev Med Chil 1991;119:1165–1170.
123.
Nagai M, Narita I, Omori K, Komura S, Arakawa M: Adrenocorticotropic hormone-independent bilateral adrenocortical macronodular hyperplasia treated with mitotane. Intern Med 1999;38:969–973.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
